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Differential phenotypes of memory CD4
and CD8 T cells in the spleen and
peripheral tissues following
immunostimulatory therapy
Gail D. Sckisel1, Annie Mirsoian1, Christine M. Minnar1, Marka Crittenden2,3, Brendan Curti2,3, Jane Q. Chen4,
Bruce R. Blazar5, Alexander D. Borowsky4, Arta M. Monjazeb6 and William J. Murphy1,7*

Abstract
Background: Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to
generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory
CD4-T cells that expand following systemic immunostimulatory therapies undergo rapid IFNg-mediated activation
induced cell death (AICD) resulting in a net loss of total CD4-T cells which correlates with elevated PD-1 expression.
This is in contrast to CD8-T cells which expand with minimal PD-1 upregulation and apoptosis. In this study we
expand upon our previous work by evaluating CD4 and CD8-T cell phenotype and distribution in peripheral organs
which are more representative of immune responses occurring at metastatic sites following immunotherapy.
Methods: Phenotypic assessment of T cells in both lymphoid (spleen and LN) as well as peripheral organs (liver and
lungs) in control and immunotherapy treated mice was performed to survey the impact of location on memory
phenotype and activation marker status. Peripheral blood from patients undergoing systemic high dose IL-2 was also
assessed for expression of PD-1 and memory phenotype.
Results: Here we reveal that, similar to what occurs in the spleen and lymph nodes, CD4-T cell numbers decreased
while CD8-T cells expanded at these peripheral sites. In contrast to having differential expression of PD-1 as occurs in
the spleen, both CD4 and CD8-T cells had significantly elevated levels of PD-1 in both the liver and lungs. Further
analysis correlated PD-1 expression to CD62Llow (T effector/effector memory,TE/EM) expression which are more
prevalent in CD4-T cells in general as well as CD8-T cells in peripheral organs. Similar elevated PD-1 expression on
TE/EM cells was observed in patients undergoing systemic high-dose IL-2 therapy.
Conclusions: These data highlight PD-1 expressing and/or TE/EM subsets of T cells in circulation as more
representative of cells at immune sites and underscore the importance of valuation both in lymphoid as well as
target organs when making determinations about immune status.
Trial registration: ClinicalTrials.gov NCT01416831. Registered August 12, 2011.
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Background
Recent technological advances in microscopy, cytometry, and advanced molecular techniques have facilitated
the evaluation of immune parameters across countless
animal models and disease states. These advances have
furthered our understanding of how various immune
cells function and interact with one another, their roles
in different diseases and disorders, as well as their responses to therapies. Often times, systemic parameters
such as peripheral blood or lymphoid organs (i.e.,
spleen, LNs, etc.) are used as surrogates for understanding both what is occurring within the organism as
a whole as well as what is occurring at effector sites.
This is particularly the case when a systemic agent is
administered or when local samples of effector sites
aren't easily accessible for complex analysis, such as
during clinical trials with human patients in which peripheral blood is the standard for immune monitoring.
Whether this practice is actually representative of what
is occurring at local sites is debatable. Studies by our
group have shown that during systemic cancer immunotherapy, regulatory T cells expand systemically in
the spleen and lymph nodes but actually decrease in
the tumor itself, thereby minimizing any negative biological effect on therapeutic outcome [1]. Furthermore,
in many murine viral studies, the practice of studying
effector sites has almost become standard.
Our lab has previously described the presence of a
unique, antigen non-specific function of conventional
memory CD8 T cells that can occur during periods of
heightened immune stimulation such as cancer immunotherapy or viral infection [2–6]. Under these conditions, memory CD8 T cells can be activated purely by
exposure to elevated cytokines causing them to expand
and upregulate markers such as NKG2D which can confer the ability to respond to target cells that are inappropriately expressing stress ligands instead of through
recognition of cognate antigen in the context of MHC,
consistent with alternative bystander activation. Importantly, we have shown that these bystander activated
memory CD8 T cells do not upregulate markers consistent with TCR engagement, namely CD25 and PD-1.
In contrast, CD4 T cells activated under the same conditions undergo proliferation which is heavily coupled
with apoptosis resulting in a net insignificant expansion of this cell type. This apoptosis was shown to be
IFNg dependent [7] and thought to be occurring
through differential expression of PD-1 on CD4 T cells
following
cytokine-induced,
antigen-independent
stimulation [8]. While we have exhaustively characterized these opposing roles in both CD4 and CD8 T cells
following systemic immunotherapy, the majority of
our conclusions have been drawn from data derived
from secondary lymphoid organs (i.e., spleen and
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lymph nodes) and not in the periphery such as the
tumor or metastatic sites.
Here we show that during treatment with immunostimulatory therapies for cancer, the bystander expansion
and activation phenotype of CD8 T cells varies greatly
by organ. Similar to our previous studies we saw that
CD8 T cells expanded in both lymphoid and peripheral
organs whereas CD4 T cells did not significantly expand
in numbers in either lymphoid or peripheral organs because in addition to proliferating, they also were undergoing apoptosis. Interestingly, we noticed that among
CD8 T cells, while the expansions were comparable
across organs, we noted that the phenotypes of these expanded cells varied in the peripheral organs compared
to the lymphoid, as peripheral organs had elevated
NKG2D, PD-1, and KLRG1. In contrast, CD4 T cell phenotypes were relatively consistent across all organs. We
show that the composition of the memory/activated
(CD44high) at a given site weighs heavily on the activation marker expression at that site with those being
more rich in the effector/effector memory T cell subsets
having elevated expression of activation markers across
the board. Importantly, PBMC samples from patients receiving systemic high dose IL-2 therapy express elevated
levels of PD-1 on the TE/EM subset as well. In summary,
these data highlight the critical need to assess immune
phenotype and function not only in lymphoid organs,
but direct sites of inflammation in order to get an accurate picture of what is occurring locally. Furthermore, it
suggests the systemic effector/effector memory population may directly correlate with the phenotype of the
cells at peripheral sites.

Methods
Mice

Female 8-12 week old female C57BL/6 or BALB/c mice
were purchased from the animal production area at the
National Cancer Institute (NCI-APA, Frederick, MD).
FVB mice were purchased from Charles River Laboratories. The MIN-O tumor model was set up as previously described [9]. All mice were housed in the animal
facilities at the University of California, Davis under
specific pathogen-free conditions and studies were approved by the UC Davis Institutional Animal Care and
Use committee.
In vivo antibodies and reagents

The agonistic anti-mouse CD40 antibody (FGK115.B3)
was generated as previously described [10]. Recombinant
human interleukin-2 (rhIL2; Teceleukin, Roche, Germany)
was provided by the National Cancer Institute (NCI,
Frederick, MD). Rat IgG (Jackson ImmunoResearch
Laboratories Inc, West Grove, PA) was used as a control for anti-CD40.
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Immunotherapeutic regimen

Mice were administered agonistic anti-CD40 and rhIL-2
as previously described [7]. Briefly, agonistic anti-CD40
or rat IgG (Jackson Immunoresearch) was administered
for 5 days (days 0-4). rhIL-2 or PBS alone was administered twice per week for 2 weeks.
Human high dose IL-2 trial

Blood samples were obtained from patients with metastatic melanoma enrolled in a randomized Phase II trial
and receiving high-dose IL-2 alone as previously described [11]. Patients began treatment on a Monday
(day 1) and high-dose IL-2 was administered at
600,000 IU/kg by i.v. bolus infusion given every 8 h for
14 planned doses depending on how well the IL-2 was
tolerated. The median number of doses in this cycle of
the study was 11. Blood samples were obtained at baseline, day 2, and day 8. The day 8 data will vary from
patient to patient depending on how many doses that
they tolerated. Peripheral blood mononuclear cells
(PBMCs) were cryopreserved from Ficoll-separated
blood and stored at -170C. Signed informed consent
was obtained before enrollment. The study was approved by the Providence Health System Regional Institutional Review Board, Oregon.
Antibodies for flow cytometry

All antibodies were purchased commercially and tested
for optimal dilution in house based on lot, clone, and
vendor. Antibodies purchased from BD Pharmingen
included purified anti-mouse CD16/32 (Fc block), PECy5 conjugated anti-human CD45RO, PE conjugated
anti-human PD-1, and allophycocyanin (APC)-Cy7 conjugated anti-mouse CD25. Antibodies purchased from
eBiosciences included FITC conjugated anti-mouse PD1, PE-Cy7 conjugated anti-mouse CD62L and NKG2D,
and PE-Cy5 conjugated anti-mouse CD62L. Antibodies
purchased from Biolegend (San Diego, CA) include
pacific blue conjugated anti-mouse CD44, brilliant violet (BV) 421 conjugated anti-human CD45RA, BV605
conjugated anti-mouse CD8, BV711 conjugated antimouse CD4 and anti-human CD4, BV785 conjugated
anti-mouse CD3, FITC conjugated anti-human CD62L,
and PE-Cy7 conjugated anti-human CD8.
Flow cytometry

In general, 106 cells for surface only stains or 2x106
cells for stains investigating intracellular antigens were
stained in round bottom 96 well plates. Surface antibodies were diluted with staining buffer (1% FBS, 1 mM
EDTA, and 0.02% NaN3 in PBS) into cocktails containing Fc block (purified anti-mouse CD16/32, BD Pharmingen, San Diego, CA) and added to cells at 45 μl per
sample. Cells were washed and resuspended in staining
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buffer for analysis within 24 h. Data were collected
using a BD Fortessa instrument running FACS DIVA software. Data were analyzed using FlowJo v10 (TreeStar,
Ashland, OR).
Data analysis and statistics

Statistical analysis was performed using Prism software
(GraphPad Software Inc.). Data were expressed as mean
± SEM. For analysis of three or more groups, the nonparametric one or two-way ANOVA test (where appropriate) was performed with the Bonferroni post-test.
Analysis of differences between two normally distributed
test groups was performed using the Student’s t-test.
Welch’s correction was applied to Student’s t-test data
sets with significant differences in variance. * P < 0.05, **
P < 0.01, *** P < 0.001.

Results
Systemic agonistic cancer immunotherapy induces
differential expansion of CD4 and CD8 T lymphocytes in
lymphoid and peripheral organs

Combination of anti-CD40 with IL-2 has been shown
to induce delayed growth and regression across several murine tumor models [6, 7, 10]. Similar to published data using cell line tumor models, treatment of
the mammary intraepithelial neoplasia-outgrowth
(MIN-O) model [9], a tissue transplant line, with antiCD40 and IL-2 immunotherapy (IT) led to significant
anti-tumor responses (P = 0.0057) including regression in >50% of the treated mice (Additional file 1:
Figure S1A). Previous studies have shown these
anti-tumor responses to be due to CD8 T cells
therefore we assessed T cell phenotype in the
spleen as well as within the tumor and lungs (a
common metastatic site for many different tumor
models). While we noted therapy generally induced
CD8 expansion across all organs, we noted some
differences in CD8 T cell memory phenotype across
organ sites (Additional file 1: Figure S1B-C).
We and others have previously shown that strong
immunostimulatory therapies for cancer induce potent
proliferation of memory (CD44high) CD4 and CD8 T
cells in the spleen and lymph nodes [6]. It was also
observed that CD4, but not CD8, T cells also undergo
activation induced cell death in an interferon(IFN)-γ
dependent fashion resulting in insignificant overall expansion of CD4 T cells by numbers in these same organs
compared to baseline [7]. These data were generated
using lymphoid organ readouts. However, in light of
phenotypes observed in the MIN-O bearing, immunotherapy treated mice, the expansion, activation, and
apoptosis of activated T cells may be differentially affected in the peripheral tissues. Therefore, we sought to
further characterize and compare T cell activation in
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In mice, CD4 and CD8 T cells can be further categorized into memory and naïve phenotypes based on
CD62L (L-selectin) and CD44 expression with the
CD44lowCD62L+ population considered naïve (TN),
CD44highCD62L+ population considered central memory (TCM), and the CD44highCD62Lneg population
considered effector and/or effector memory (TE/EM). It
is known that CD4 and CD8 T cells differ in their distribution of these subsets in lymphoid and peripheral
organs. While naïve frequencies within CD4 and CD8
populations remain relatively similar, the CD44high
population is more central memory skewed in CD8 T
cells and effector memory skewed in CD4 T cells in a
resting organism [12, 13]. However, in the peripheral
organs, tissue resident T cells within both the CD4 and
CD8 T cell subsets are predominantly of the effector
memory phenotype [14].
Previous studies have shown that memory phenotype
cells (CD44high) are the main cell type expanding following stimulatory immunotherapies [6]. To better
understand the composition of CD4 and CD8 T cells
across various organs, we evaluated their memory
phenotype status in each organ following IT. At rest,
the CD44high population of CD8 T cells in the lymphoid
organs was predominantly TCM (>90%) whereas in the
peripheral organs, it was a combination with ~60%
TCM (Fig. 3a, c, e,-f ). In general, IT results in an overall
expansion in the CD44high frequency across all organs.
The TCM frequencies were either unchanged or slightly
increased, while the TE/EM populations significantly
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from controls (Fig C-D). In contrast, total CD4 T cell
frequency decreased and numbers did not change significantly compared to controls within the same organs
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total numbers. These data were in line with what was
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similar trends in both CD4 and CD8 T cells, namely
that CD8 T cells were expanding and surviving across
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Fig. 1 CD4 and CD8 T cells have differential proliferative and apoptotic responses to immunostimulatory therapies in lymphoid organs. Mice
were treated with anti-CD40/IL-2 immunotherapy and assessed for various immune parameters on day 12 of treatment in lymphoid (spleen or
LN) organs. Percentage (a) and total numbers (b) of CD4 (Foxp3-ve) and CD8 T cells in lymphoid organs. Percentage of proliferating (c), as
assessed by BrdU, and apoptotic (d), as assessed by surface Annexin V expression, of CD4 (Foxp3-ve) and CD8 T cells in lymphoid organs. These
data are representative of 2-5 independent experiments with 3 mice per group. Data are presented as mean ± SEM. Statistics were derived using
ANOVA with Bonferroni’s post-test, *P < 0.05, **P < 0.01, ***P < 0.001, ns: P > 0.05
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Fig. 2 CD4 and CD8 T cells have differential proliferative and apoptotic responses to immunostimulatory therapies in peripheral organs. Mice
were treated with anti-CD40/IL-2 immunotherapy and assessed for various immune parameters on day 12 of treatment in peripheral (lungs or
liver) organs. Percentage (a) and total numbers (b) of CD4 (Foxp3-ve) and CD8 T cells in peripheral organs. Percentage of proliferating (c), as
assessed by BrdU, and apoptotic (d), as assessed by surface Annexin V expression, of CD4 (Foxp3-ve) and CD8 T cells in peripheral organs. These
data are representative of 2-3 independent experiments with 3 mice per group. Data are presented as mean ± SEM. Statistics were derived using
ANOVA with Bonferroni’s post-test, *P < 0.05, **P < 0.01, ***P < 0.001, ns: P > 0.05

expanded (Fig. 3e-f ) from ~10% to 30% in the lymphoid
organs and, impressively, from ~30-85% in the peripheral organs.
Within the CD44high population of the CD4 T cells, resting mice were more heavily skewed towards the TE/EM
phenotype with approximately 60-70% in the lymphoid
and 75-95% in the peripheral tissues (Fig. 3b, d). As occurred in the CD8 T cells, following IT the CD44high proportion expanded but due to the fact that it was so heavily
skewed to the TE/EM phenotype across all organs in resting
mice, the frequencies of CD4 TE/EM were largely consistent across all organs in IT-treated mice (Fig. 3e). The TCM
CD4 frequencies remained relatively low and consistent
across all organs, both pre- and post-IT (Fig. 3f).
Expression of activation markers in CD4 and CD8 T cells is
dependent upon location and memory phenotype

In addition to differences in proliferation and apoptosis,
we have also routinely noticed that CD4 and CD8 T cells
differentially upregulate activation and inhibitory molecules following IT. The most notable example of this
being PD-1 which, based on studies focusing on secondary lymphoid organs (spleen and LN), was preferentially
upregulated on CD4 and not CD8 T cells and thought to
likely be involved in the preferential AICD process that
occurred in CD4 but not CD8 T cells following IT [7].
Another example would be the preferential upregulation
of NKG2D on CD8 T cells but not CD4 conferring
bystander-induced lytic capability following strong cytokine exposure to the memory CD8 subset. Previous
studies by our lab as well as data presented in Fig. 3 have
shown that among both CD4 and CD8 T cells, the primary cells that actively proliferate and respond to IT are

the CD44high memory phenotype cells [6]. Therefore, we
next focused on this population.
In the CD44high population, it has been shown that the
proliferating CD8 T cells fail to upregulate markers consistent with activation by an antigen specific stimulus
such as CD25 and PD-1, yet upregulate markers that
allow them to acquire a bystander phenotype, namely
NKG2D, conferring the ability to act more in an NKlike, antigen unrestricted manner. Conversely, CD44high,
proliferating (Foxp3neg) CD4 T cells disproportionately
upregulate PD-1 (in contrast to CD8 T cells and Foxp3+,
regulatory CD4 T cells) which we have suggested allows
them to be preferentially targeted for induction of apoptosis [8]. Consistent with these previous reports, we
observed similar phenotypes among splenic and lymph
node resident, IT-treated CD44highCD8+ T cells, which
significantly upregulated NKG2D but not PD-1 (Fig. 4a, c),
and CD44highCD4+ T cells, which robustly upregulated
PD-1, yet not NKG2D (Fig. 4b, d). When we assessed
the same phenotypic markers in the T cell populations
resident to peripheral, non-lymphoid organs, the
CD44highCD8+ T cell phenotype was considerably different from that of those resident to the secondary
lymphoid organs. While CD44highCD8+ T cells resident
to the lungs and liver were still NKG2D+CD25neg
(Fig. 4a, c), the frequency of NKG2D+ cells in this
population appeared to increase from 20-30% in the
lymphoid organs to 40–50% in the peripheral organs
(Fig. 4a). Furthermore, in contrast to lymphoid organs
where PD-1 expression was unchanged, PD-1 expression was increased significantly in both the lungs and
liver following IT in the CD44highCD8+ population
(Fig. 4c). Conversely, CD44highCD4 T cell phenotype
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was remarkably similar to spleen and lymph node CD4
T cells across all organs (Fig. 4b, d) with comparable
expression of PD-1, and minimal upregulation of
NKG2D. CD25 was not upregulated in CD4 or CD8 T
cells at any site (data not shown). This was unexpected
because we have previously suggested that the differential expression of PD-1 was likely the underlying mechanism of the differential induction of apoptosis between
CD4 and CD8 T cells following strong, immunostimulatory IT regimens. Yet, in the peripheral organs, CD4
T cells continue to be disproportionately affected by
apoptosis despite the fact that PD-1 expression is comparable between CD4 and CD8 T cells. This pattern
that emerged was also interesting because the increased
activation marker expression in the periphery appeared

to directly correlate with TE/EM predominance, particularly in the case of PD-1.
It has recently been shown that circulating TE/EM cells
express elevated levels of PD-1 in resting humans [15].
Therefore, we hypothesized that CD8+ TE/EM cells may
be preferentially expressing these activation markers
over CD8+ TCM resulting in differential frequencies of
CD44highCD8+ T cells expressing activation markers in
secondary lymphoid and peripheral organs following IT.
Therefore, we evaluated NKG2D and PD-1 expression
on CD8 + CD44highCD25neg TE/EM and TCM cells across
all organs in resting and IT-treated mice. In control
mice, both NKG2D (Fig. 5a) and PD-1 (Fig. 5c) were
expressed at a higher frequency on the TE/EM subset of
the CD8+CD44highCD25- population. However, the
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overall frequency of the TE/EM population among CD8+
T cells in resting mice is relatively low compared to TCM
(pie charts Fig. 5a), therefore, overall the expression of
both PD-1 and NKG2D is predominantly low (Fig. 4) as
TCM makes up the majority of CD8+ T cells at rest. In
SP

% NKG2D+
of MP CD25-CD8+ T cells

A

60

LN

LV

LG

Control Group:
% NKG2D+ by Memory Phenotype

SP

LN

LV

B
60
40

20

20

IT Group:
% NKG2D+ by Memory Phenotype

*
***

0

***

***

Spleen LN

***

Liver

***

LG
EM
CM
(overall)

40

EM
CM

***
**

0

Lungs

C
% PD1+
of MP CD25-CD8+ T cells

the immunotherapy treated mice, both the NKG2D and
PD-1 expression were increased across all organs (Fig. 4).
Once again, both NKG2D (Fig. 5b) and PD-1 (Fig. 5d)
were expressed more highly on the TE/EM CD8+ T cells
than the TCM CD8+ T cells. In the lymphoid organs,

Spleen LN

Liver

Lungs

D
100

Control Group:
% PD1+ by Memory Phenotype

80

80

IT Group:
% PD1+ by Memory Phenotype

60

60

40

40
20
0

EM
CM

ns

*

**

***

Spleen LN

20

ns
***

**

**

0
Liver

Lungs

Spleen LN

Liver

Lungs

Fig. 5 Differential phenotypes of CD8 T cells by location correlates with enhanced expansion and activation marker upregulation on the effector/
effector memory T cell phenotype. Mice were treated with anti-CD40/IL-2 immunotherapy and assessed for various immune parameters on day
12 of treatment in lymphoid (spleen or LN) or peripheral (lungs or liver) organs. Frequencies of NKG2D+ (a-b) and PD-1+ (c-d) in CD25negCD44highCD8+
T cells in control (a, c) and anti-CD40/IL-2 (b, d) treated mice as stratified by TCM (CD62L+, white) and TE/EM (CD62L-, black). These data are representative
of 2-3 independent experiments with 3 mice per group. Data are presented as mean ± SEM. Statistics were derived using ANOVA with Bonferroni’s
post-test, *P < 0.05, **P < 0.01, ***P < 0.001
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where the TE/EM population expanded compared to control, it was still significantly less than CD8+ TCM cells
(pie charts, Fig. 5b) resulting in less significant expansions at these sites. Contrary to lymphoid organs, CD8+
TE/EM cells made up the majority of the peripheral organs assayed (pie charts, Fig. 5b) thereby making the
overall expression of NKG2D and PD-1 significantly
higher at these sites. Again it is important to note that
in the lymphoid organs of immunotherapy-treated mice,
the overall expression of both activation markers was
significantly lower than in the peripheral organs due to
the TCM skewing in the lymphatics over the periphery in
the CD8 population. The expression levels didn't vary
greatly among TE/EM from different organs (there were
no significant differences between lymphoid and peripheral organs) within the same treatment groups but did
generally increase in the IT-treated compared to control,
a trend that was more significantly pronounced with
NKG2D than PD-1 (Fig. 5). In contrast, TCM activation
marker expression remained relatively constant not only
among organs from mice within a treatment group, but
between control and IT-treated groups as well (Fig. 5a-b).
Taken together, these data suggest that the constitution of
the memory/activated pool (TCM vs TE/EM) weighs heavily
upon the phenotype of the activated T cell population,
particularly with CD8 T cells as their constitution varies
greatly between lymphoid and non-lymphoid organs.
Assessment of T cells from patients receiving high dose
systemic immunostimulatory therapy

Next we wanted to assess whether these results translated into human patients receiving immunostimulatory
therapies for cancer. There are currently no trials assessing combination agonistic anti-CD40 with recombinant
human IL-2 however we have routinely compared our
combination therapy to other systemic immunostimulatory treatments including high dose TLR agonists and
high dose systemic cytokine therapies and shown similar
phenotypic and functional changes to T cells as are observed in our preclinical model [5, 16]. To assess
whether patients in the clinic displayed similar changes
in surface marker expression, we collected peripheral
blood mononuclear cells (PBMCs) from metastatic melanoma patients undergoing systemic high dose IL-2
therapy. Patients received 6x10^5 IU/Kg every 8 h for a
planned total of 14 doses. PBMC samples were collected
one day prior to the start of therapy (baseline) or on day
8 of the first cycle of therapy (day 8) to assess T cell
phenotype. Comparing baseline and day 8 samples, there
was a significant increase in PD-1+ memory phenotype
(CD45RO+) cells in both the CD4 and CD8 T cell subsets following high dose IL-2 therapy (Fig. 6a-c). When
this population was further broken down into central
memory (CD62L+) and effector/effector memory

Page 8 of 11

(CD62L-) at the day 8 time point, the effector/effector
memory subset expressed significantly higher PD-1 expression than the central memory subset (Fig. 6d-e).
Together, these data correlate with what was observed in
murine studies suggesting that these data are applicable
to human studies and may be an indicator of what is occurring locally.

Discussion
Our previous studies have shown that treatment with
systemic immunostimulatory therapies for cancer results
in preferential induction of apoptosis in the CD4 T cell
population in an IFNg-dependent mechanism [7]. We
further built upon that study suggesting that it was the
preferential induction of PD-1 on the CD4 T cell effector
population (as opposed to regulatory CD4 or CD8 T
cells) that was responsible for their bias to activation induced cell death [8]. This study suggests that this may
not actually be the case in that PD-1 expression in CD8
T cells in peripheral organs is actually significantly elevated, much more so than CD4 T cells in the lymphoid
organs following IT, yet they continue to expand without
inducing elevated levels of apoptosis. This would suggest
a role for PD-1 that is more in line with its function as
an acute activation marker in activated cells [17, 18] rather than its function in inducing apoptosis as occurs
during exhaustion [19–21]. This study again underscores
the necessity for evaluating multiple organ sites when
drawing conclusions, particularly during murine studies
where this can be easily done.
Given that the majority of studies evaluating immune
parameters do not directly examine target tissues but
examine peripheral blood or take biopsies from lymphoid organs (for example, whole spleens in mice or LN biopsies in humans), this study suggests that we are not
getting accurate measures of what is truly occurring at
important effector sites when looking at frequencies and
counts of overall populations. For example, PD-1 expression was not significantly upregulated (less than ~20%)
in the spleen and lymph nodes of immunotherapy
treated mice but was greater than ~40% in the lungs and
liver (Fig. 4). These data underscore the need to consistently evaluate immune parameters across as many organ
sites as possible in order to get an accurate picture of
what is occurring in the organism as a whole. Indeed, in
many clinical trials involving immunotherapies for cancer, it has proven difficult to pin point correlates of objective responses in peripheral blood. In this study,
correlations were drawn with the composition of the
memory phenotypes of different T cell populations with
the actual activation marker phenotypes observed in the
population as a whole (Fig. 5). In general, we saw that
the TE/EM population, while smaller overall in the
lymphoid organs, was relatively accurate as to the overall
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phenotype of the activated T cells at effector sites (peripheral organs). While many human clinical trials aren't
able to fully evaluate effector sites, this may become a
powerful tool moving forward as it may prove useful to
look for correlates of objective responses focusing on the
TE/EM phenotype which appears to mimic the effector
site more closely (assuming that the effector site is a not
a lymphoid organ). Indeed, a recent study by Gros et al.
showed that only the T cells expressing PD-1 (and by extrapolation of work presented within this paper likely of
the TE/EM phenotype) in the peripheral blood shared
TCR specificity with tumor infiltrating lymphocytes
found in the tumor [22]. Additionally, while the data is
not shown in the current study, the phenotype of T cells
within tumors following systemic immunostimulatory
therapies such as anti-CD40/IL-2 or systemic high dose
IL-2 have previously been extensively characterized

[7, 10]. In the case of these systemic immunostimulatory
regimens, it is important to consider T cell phenotypes
without tumor burden as the overwhelming majority of
the T cells activated in tumor bearing studies are antigen
non-specific bystander memory T cells. These nonspecific bystander CD8 T cells have a prominent role in
tumor clearance as has been previously shown [5, 6]. In
order to reconcile this, however, we show that the
phenotype of T cells in the tumor is comparable to that
in the tissues thus highlighting the relevance of using tissues that are often targets of metastatic sites (i.e. liver
and lungs) by demonstrating T cells phenotypes from
the MINO tumor model as well as lungs and spleen
(Additional file 1: Figure S1).
Altogether, we show that following cancer immunotherapy we can observe a similar population of bystander activated CD8 T cells whose expression of
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different key activation markers varies greatly depending
upon their location within the body and the composition
of the memory T cell pool at that location. Following activation, bystander memory T cells are generated from 1)
central memory T cells and/or 2) effector memory T
cells, with the effector memory T cells being phenotypically similar to effector T cells. The locations of these
cells vary with subset (4 vs 8) and memory phenotype
(naïve vs central memory vs effector memory). In general, the memory proportion of the CD4 subset is more
heavily TE/EM skewed within the lymphoid organs at rest
comprising a CD4 population made up predominantly of
naïve and E/EM cells [12, 13]. In contrast, the memory
proportion of the CD8 subset is more heavily TCM
skewed within the lymphoid compartment at rest comprising a CD8 population made up predominantly of
naïve and central memory cells [12, 13]. Contrary to differential distribution within the lymphoid compartment,
the memory populations of both the CD4 and CD8 subsets in the peripheral, tissue resident populations is
largely effector/effector memory skewed. [14] Our studies revealed that CD8 TCM had relatively lessened
expression of key activation markers such as NKG2D
and PD-1 whereas CD8 TE/EM had relatively heightened
expression of the same markers (Fig. 5). Therefore, the
composition of the memory pool at different sites
weighed heavily on the overall expression of those
markers in the memory pool. This made it appear as if
the expression of these key markers may be changing at
different sites when in fact it was the composition of the
bystander activated population (TCM vs TE/EM) that was
actually altered.
Finally, expression of activation markers and T cell
memory phenotype distribution changes over the course
of a lifespan with variables such as age, body fat content,
and pathogen status (such as SPF vs non-SPF), among
other things. Now that we are beginning to appreciate
the impact of each of these conditions on responses to
infectious disease, responses to immunomodulatory
treatments, and even the maintenance of homeostasis
(as compared to young, non-obese, SPF counterparts), it
is important to understand and assess how differences at
baselines can affect outcomes across all organs. For example, obese and aged mice generally express elevated
PD-1 [23] (and manuscript in progress) on T cells and
have been shown to have a skewed memory phenotype
[23–25]. What has not been thoroughly assessed in these
mice is whether the PD-1 is predominantly on the TE/EM
populations that the T cells are skewed into which this
study would suggest may be the underlying root of the
distorted PD-1 expression. In conclusion, we have presented data herein illustrating the differences in activation marker expression based on memory phenotype
which varies between lymphoid and non-lymphoid
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organs both at rest and during an active immune response. These data underscore the necessity to thoroughly investigate both lymphoid and peripheral sites
before drawing conclusions based on cell phenotype and
function.

Conclusions
In summary, we show that there can be significant differences in T cell phenotype based on location of the cells
within lymphoid organs or at peripheral sites. In particular, the TE/EM subset of T cells in lymphoid organs more
accurately reflect the phenotype of T cells at the peripheral
sites. These data highlight PD-1 expressing and/or TE/EM
subsets of T cells in circulation as more representative of
cells at immune sites and underscore the importance of
valuation both in lymphoid as well as target organs when
making determinations about immune status.
Additional file
Additional file 1: Figure S1. Differential T cell phenotypes in lymphoid
vs primary tumor and metastatic sites following anti-CD40/IL-2 immunotherapy.
MIN-O mice were developed as previously described. (9). Once tumors
were palpable within MIN lesions, mice were treated with anti-CD40/IL-2
immunotherapy. On day 9 of therapy, mice were taken down to assess T
cell phenotypes in the spleen, lungs, and tumor. (A) Survival of control and
anti-CD40/IL-2 (40/2) treated MIN-O mice. (B-C) Representative dot plots of
CD8+ T cell phenotypic analysis in control and immunotherapy treated
MIN-O mice. Data are representative of 1-2 independent experiments.
(PDF 882 kb)
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